Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says

(MedPage Today) -- Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables, Eli Lilly announced on Wednesday.
In topline data from the...